Pharmaceutical News RSS Feed - Pharmaceutical News

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology. [More]
2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
New treatment for Marfan syndrome works as well as beta blockers

New treatment for Marfan syndrome works as well as beta blockers

A new treatment for Marfan syndrome, a rare genetic disease that can lead to heart problems, works as well as the currently recommended medical therapy, beta blockers, according to an article in the New England Journal of Medicine. [More]
No added benefit proven for empagliflozin in type 2 diabetes

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]
Changes in lipid layer of tear film may contribute to contact lens discomfort

Changes in lipid layer of tear film may contribute to contact lens discomfort

Changes in the lipid layer of the eyes' natural tear film may contribute to the common problem of contact lens discomfort, reports a study in the December issue of Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
Cocaine disrupts woman's estrus cycle, may explain sex differences in cocaine addiction

Cocaine disrupts woman's estrus cycle, may explain sex differences in cocaine addiction

Women are more sensitive to the effects of cocaine and more susceptible to cocaine abuse than men. Cocaine's ability to disrupt a woman's estrus cycle may explain the sex differences in cocaine addiction, and new evidence that caffeine may be neuroprotective and able to block cocaine's direct effects on the estrus cycle reveals novel treatment possibilities, according to an article published in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Study shows blood pressure medication is not linked to breast cancer

Study shows blood pressure medication is not linked to breast cancer

Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug, according to new study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah. [More]

Endo International announces commercial availability of generic product, Valcyte

Endo International plc today announced that its Qualitest subsidiary has launched a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg). [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

Drugs for brain diseases such as Alzheimer's, Parkinson's, and motor neurone disease that have stalled in development could be revived thanks to the efforts of a global coalition of non-profit organizations and funders announced today. [More]
Researchers find drug combination that reduces risk of skin graft rejection

Researchers find drug combination that reduces risk of skin graft rejection

A research team bringing together José Cohen and Philippe Grimbert (Inserm Unit 955/Université Paris Est Créteil [UPEC] and the Centre for Clinical Investigation - Biotherapies 504 [CIC-BT 504]), and their collaborators at Institut Curie and AP-HP (George Pompidou European Hospital) has succeeded in finding a combination of drugs that reduces the risk of rejection following a skin graft. [More]
Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. [More]
BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML). [More]
New study identifies crizotinib drug as possible new coating for drug-eluting stents

New study identifies crizotinib drug as possible new coating for drug-eluting stents

A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. [More]
TSRI scientists reveal how ZMapp antibodies target Ebola virus

TSRI scientists reveal how ZMapp antibodies target Ebola virus

Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. [More]
Common anti-malaria medicine could have significant impact on colorectal cancer

Common anti-malaria medicine could have significant impact on colorectal cancer

Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

The type 3 interferons - usually called the “lambda” interferons, or “IFNL” - are the most recently identified IFNs. We (myself and Sergei Kotenko) originally identified the receptor and then the three ligands (IFNL1,2,3; very recently a fourth, IFNL4, was discovered); the key paper was published in 2003. [More]
Investigational treatment shows promise against Marfan syndrome

Investigational treatment shows promise against Marfan syndrome

An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta. [More]